Inozyme Pharma CEO Buys 2,815 Shares Through Employee Stock Program

Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).

Rhea-AI Filing Summary

Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).

Key Transaction Details:

• Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
• Total shares owned after transaction: 43,861 shares
• Ownership type: Direct
• ESPP purchase period: April 1, 2025 - June 25, 2025

The transaction was executed under the company's 2020 ESPP, which allows employees to purchase company stock at a discount. This insider purchase by the CEO demonstrates continued alignment with shareholder interests and potential confidence in the company's prospects.

Insider Trade Summary

Grant/Award: 2,815 shares

Grant/Award 1 txn

Insider Treco Douglas A

Role CEO & Chairman

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,815	$0.74	$2K

Holdings After Transaction: Common Stock — 43,861 shares (Direct)

Footnotes (1)

1. F1. Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of INZY stock did CEO Douglas Treco purchase on June 25, 2025?

CEO Douglas Treco purchased 2,815 shares of INZY common stock on June 25, 2025 through the company's Employee Stock Purchase Plan (ESPP).

What was the purchase price for INZY shares in the ESPP transaction?

The shares were purchased at $0.74 per share, which represents 85% of the closing price of Inozyme's common stock on April 1, 2025 (the first trading day of the purchase period).

How many INZY shares does Douglas Treco own after this purchase?

Following this ESPP transaction, Douglas Treco directly owns 43,861 shares of INZY common stock.

What positions does Douglas Treco hold at INZY?

Douglas Treco serves as both CEO & Chairman and Director at Inozyme Pharma, Inc.

When was the ESPP purchase period for this INZY stock transaction?

The ESPP purchase period ran from April 1, 2025 through June 25, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/27/2025 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Treco Douglas A

(Last) (First) (Middle)

C/O INOZYME PHARMA, INC.

321 SUMMER STREET SUITE 400

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inozyme Pharma, Inc. [ INZY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Chairman

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2025		A(1)	V	2,815	A	$0.74	43,861	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period.

	/s/ Sanjay Subramanian, as attorney-in-fact for Douglas A. Treco	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.